



## PEER-REVIEW REPORT

**Name of journal:** World Journal of Gastroenterology

**Manuscript NO:** 56685

**Title:** Real-world Treatment Attrition Rates in Advanced Esophagogastric Cancer

**Reviewer's code:** 04022629

**Position:** Peer Reviewer

**Academic degree:** FRCS (Gen Surg), PhD

**Professional title:** Academic Fellow, Academic Research

**Reviewer's Country/Territory:** China

**Author's Country/Territory:** Canada

**Manuscript submission date:** 2020-05-10

**Reviewer chosen by:** Jia-Ping Yan

**Reviewer accepted review:** 2020-05-22 17:54

**Reviewer performed review:** 2020-05-29 01:33

**Review time:** 6 Days and 7 Hours

<b>Scientific quality</b>	<input type="checkbox"/> Grade A: Excellent <input type="checkbox"/> Grade B: Very good <input checked="" type="checkbox"/> Grade C: Good <input type="checkbox"/> Grade D: Fair <input type="checkbox"/> Grade E: Do not publish
<b>Language quality</b>	<input type="checkbox"/> Grade A: Priority publishing <input checked="" type="checkbox"/> Grade B: Minor language polishing <input type="checkbox"/> Grade C: A great deal of language polishing <input type="checkbox"/> Grade D: Rejection
<b>Conclusion</b>	<input type="checkbox"/> Accept (High priority) <input type="checkbox"/> Accept (General priority) <input checked="" type="checkbox"/> Minor revision <input type="checkbox"/> Major revision <input type="checkbox"/> Rejection
<b>Re-review</b>	<input checked="" type="checkbox"/> Yes <input type="checkbox"/> No
<b>Peer-reviewer statements</b>	Peer-Review: <input checked="" type="checkbox"/> Anonymous <input type="checkbox"/> Onymous Conflicts-of-Interest: <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No



**Baishideng  
Publishing  
Group**

7041 Koll Center Parkway, Suite  
160, Pleasanton, CA 94566, USA  
**Telephone:** +1-925-399-1568  
**E-mail:** [bpgoffice@wjgnet.com](mailto:bpgoffice@wjgnet.com)  
**https://**[www.wjgnet.com](https://www.wjgnet.com)

#### **SPECIFIC COMMENTS TO AUTHORS**

The authors of this manuscript try to characterize real-world treatment attrition rates between lines of therapy for patients with advanced esophagogastric cancer. The authors argued that improved survival was associated with better baseline ECOG and increased lines of therapy. Although the conception and data of the present paper could be of some interest, the design and results are sometimes not quite clear, and there are some issues should be addressed. 1. The title of this manuscript is about esophagogastric cancer, but the background only introduced gastric cancer. 2. Advanced EGC should be defined in the manuscript. 3. It is well known that radiotherapy plays an important role in unresectable locally advanced EGC. Why was it not mentioned in the treatment details? 4. Why did “gender” appear in Table 1? Please correct it. 5. Where was the relevant data about Fourth-line chemotherapy backbone in Table 2? Please provide the information.



### PEER-REVIEW REPORT

**Name of journal:** World Journal of Gastroenterology

**Manuscript NO:** 56685

**Title:** Real-world Treatment Attrition Rates in Advanced Esophagogastric Cancer

**Reviewer's code:** 02982252

**Position:** Peer Reviewer

**Academic degree:** MD

**Professional title:** Professor

**Reviewer's Country/Territory:** Italy

**Author's Country/Territory:** Canada

**Manuscript submission date:** 2020-05-10

**Reviewer chosen by:** Jia-Ping Yan

**Reviewer accepted review:** 2020-05-22 05:35

**Reviewer performed review:** 2020-06-07 12:37

**Review time:** 16 Days and 7 Hours

<b>Scientific quality</b>	<input type="checkbox"/> Grade A: Excellent <input type="checkbox"/> Grade B: Very good <input checked="" type="checkbox"/> Grade C: Good <input type="checkbox"/> Grade D: Fair <input type="checkbox"/> Grade E: Do not publish
<b>Language quality</b>	<input checked="" type="checkbox"/> Grade A: Priority publishing <input type="checkbox"/> Grade B: Minor language polishing <input type="checkbox"/> Grade C: A great deal of language polishing <input type="checkbox"/> Grade D: Rejection
<b>Conclusion</b>	<input type="checkbox"/> Accept (High priority) <input type="checkbox"/> Accept (General priority) <input checked="" type="checkbox"/> Minor revision <input type="checkbox"/> Major revision <input type="checkbox"/> Rejection
<b>Re-review</b>	<input checked="" type="checkbox"/> Yes <input type="checkbox"/> No
<b>Peer-reviewer statements</b>	Peer-Review: <input checked="" type="checkbox"/> Anonymous <input type="checkbox"/> Onymous Conflicts-of-Interest: <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No



**Baishideng  
Publishing  
Group**

7041 Koll Center Parkway, Suite  
160, Pleasanton, CA 94566, USA  
**Telephone:** +1-925-399-1568  
**E-mail:** [bpgoffice@wjgnet.com](mailto:bpgoffice@wjgnet.com)  
**https://**[www.wjgnet.com](http://www.wjgnet.com)

#### **SPECIFIC COMMENTS TO AUTHORS**

This is a well-documented real-life data report, gauging the use of multiple therapy lines for metastatic esophagogastric cancer (therefore , outside of clinical trials published data). The Authors took advantage on the fact that in British Columbia there is a Cancer Provincial Database providing records for six cancer centres. The study is interesting , even it shows some limitations as in its retrospective nature and in the limited time span and subsequent number of examined records. Nevertheless , in 245 patients there was a high level of treatment attrition, with 50% receiving just one line of therapy, whereas improved survival seems associated with increased lines of therapy. The Authors should be congratulated for pointing out that steep attrition rates claim for more efficacious early-line treatment options; nevertheless I would suggest a minor review , opting for a less lengthy background discussion, but with a deeper focus on the real cause-effect events which are at the base of such phenomenon and a brief reappraisal of cancer therapy attrition in different geographical and socio-economical conditions.



**RE-REVIEW REPORT OF REVISED MANUSCRIPT**

**Name of journal:** World Journal of Gastroenterology

**Manuscript NO:** 56685

**Title:** Real-World Treatment Attrition Rates in Advanced Esophagogastric Cancer

**Reviewer’s code:** 04022629

**Position:** Peer Reviewer

**Academic degree:** FRCS (Gen Surg), PhD

**Professional title:** Academic Fellow, Academic Research

**Reviewer’s Country/Territory:** China

**Author’s Country/Territory:** Canada

**Manuscript submission date:** 2020-05-10

**Reviewer chosen by:** Ya-Juan Ma

**Reviewer accepted review:** 2020-07-27 12:25

**Reviewer performed review:** 2020-07-27 12:27

**Review time:** 1 Hour

<b>Scientific quality</b>	<input type="checkbox"/> Grade A: Excellent <input checked="" type="checkbox"/> Grade B: Very good <input type="checkbox"/> Grade C: Good <input type="checkbox"/> Grade D: Fair <input type="checkbox"/> Grade E: Do not publish
<b>Language quality</b>	<input checked="" type="checkbox"/> Grade A: Priority publishing <input type="checkbox"/> Grade B: Minor language polishing <input type="checkbox"/> Grade C: A great deal of language polishing <input type="checkbox"/> Grade D: Rejection
<b>Conclusion</b>	<input type="checkbox"/> Accept (High priority) <input checked="" type="checkbox"/> Accept (General priority) <input type="checkbox"/> Minor revision <input type="checkbox"/> Major revision <input type="checkbox"/> Rejection
<b>Peer-reviewer statements</b>	Peer-Review: <input checked="" type="checkbox"/> Anonymous <input type="checkbox"/> Onymous Conflicts-of-Interest: <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No

**SPECIFIC COMMENTS TO AUTHORS**

The concerns have been well addressed